Calciphylaxis Market: Rapid Growth & Investment Outlook to 2034 - DelveInsight

DelveInsight's "Calciphylaxis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Calciphylaxis, historical and forecasted epidemiology as well as the Calciphylaxis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Calciphylaxis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Calciphylaxis Market Forecast
https://www.delveinsight.com/sample-request/calciphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Calciphylaxis Market Report:
• The Calciphylaxis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In July 2025, BioMarin finalized its acquisition of Inozyme Pharma for USD 4.00 per share in an all-cash transaction valued at around USD 270 million. This deal broadened BioMarin's enzyme therapy portfolio by adding INZ-701, currently in development for three rare, progressive genetic disorders affecting blood vessels, soft tissue, and bone.
• In June 2025, FDA approval boosts market prospects for SolasCure's ulcer therapy. The US Food and Drug Administration has granted Fast Track Designation to Cambridge-based biotech SolasCure for its investigational Aurase Wound Gel (AWG) for treating calciphylaxis ulcers. This designation highlights AWG's potential in managing this indication, broadening its role in chronic wound healing and accelerating the timeline for patient access to the therapy.
• Marin et al. (2023) reported that among patients on maintenance hemodialysis, the incidence of calciphylaxis is estimated at 3.49 cases per 1,000 patient-years.
• According to Altman et al. (2019), calciphylaxis occurs at an annual rate of 35 cases per 10,000 patients in the United States.
• Globally, the annual incidence of calciphylaxis is estimated to range between 1 and 35 cases per 10,000 dialysis patients.
• A study by Chinnadurai et al. (2021) in the UK reported that calciphylaxis affects 1% to 4% of dialysis patients, with an estimated yearly incidence of around 0.04%. The condition carries a significant mortality risk, with annual death rates reaching up to 60%.
• The epidemiology of calciphylaxis is projected to evolve over the forecast period from 2025 to 2034.
• Westphal et al. (2022) indicate that calciphylaxis may occur independently of kidney disease, although it predominantly affects patients with severe renal failure. The occurrence of calciphylaxis among dialysis patients varies between 0.04% and 4%, with an apparent increase in incidence observed over the past decade.
• Emerging therapies such as SNF472, INZ-701, and others are showing promising top-line results in their clinical trials, positioned in the mid-phase stages. These treatments are poised to strengthen the pipeline upon their anticipated launch.
• Key Calciphylaxis Companies: Inozyme Pharma, Sanifit, Shire, Hope Pharmaceuticals, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., Laboratoris Sanifit S.L, and others
• Key Calciphylaxis Therapies: INZ-701, SNF472, lanthanum carbonate, Sodium Thiosulfate, and others
• The Calciphylaxis epidemiology based on gender analyzed that the Incident Cases of Calciphylaxis is higher in females than in males
• The Calciphylaxis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Calciphylaxis pipeline products will significantly revolutionize the Calciphylaxis market dynamics.

Calciphylaxis Overview
Calciphylaxis, also known as calcific uremic arteriolopathy, is a rare and severe vascular condition primarily seen in patients with end-stage kidney disease. It involves the accumulation of calcium deposits in small blood vessels, leading to tissue ischemia, necrosis, and ulceration, often affecting the skin but potentially impacting other organs as well.

Get a Free sample for the Calciphylaxis Market Report:
https://www.delveinsight.com/report-store/calciphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Calciphylaxis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Calciphylaxis Epidemiology Segmentation:
The Calciphylaxis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Incident Cases of Patients on Hemodialysis in the 7MM
• Total Incident Cases of Calciphylaxis in Patients on Hemodialysis in the 7MM
• Gender-specific Incident Cases of Calciphylaxis in the 7MM

Download the report to understand which factors are driving Calciphylaxis epidemiology trends @ Calciphylaxis Epidemiology Forecast
https://www.delveinsight.com/sample-request/calciphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Calciphylaxis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Calciphylaxis market or expected to get launched during the study period. The analysis covers Calciphylaxis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Calciphylaxis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Calciphylaxis Therapies and Key Companies
• INZ-701: Inozyme Pharma
• SNF472: Sanifit
• lanthanum carbonate: Shire
• Sodium Thiosulfate: Hope Pharmaceuticals

Discover more about therapies set to grab major Calciphylaxis market share @ Calciphylaxis Treatment Market
https://www.delveinsight.com/sample-request/calciphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Calciphylaxis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Calciphylaxis Companies: Inozyme Pharma, Sanifit, Shire, Hope Pharmaceuticals, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., Laboratoris Sanifit S.L, and others
• Key Calciphylaxis Therapies: INZ-701, SNF472, lanthanum carbonate, Sodium Thiosulfate, and others
• Calciphylaxis Therapeutic Assessment: Calciphylaxis current marketed and Calciphylaxis emerging therapies
• Calciphylaxis Market Dynamics: Calciphylaxis market drivers and Calciphylaxis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Calciphylaxis Unmet Needs, KOL's views, Analyst's views, Calciphylaxis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.